DK2486051T3 - Farmaceutisk præparat, der omfatter rekombinant hcg - Google Patents
Farmaceutisk præparat, der omfatter rekombinant hcg Download PDFInfo
- Publication number
- DK2486051T3 DK2486051T3 DK10763000.6T DK10763000T DK2486051T3 DK 2486051 T3 DK2486051 T3 DK 2486051T3 DK 10763000 T DK10763000 T DK 10763000T DK 2486051 T3 DK2486051 T3 DK 2486051T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical preparation
- preparation containing
- containing recombinant
- recombinant hcg
- hcg
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09252360 | 2009-10-05 | ||
| PCT/GB2010/001854 WO2011042688A1 (en) | 2009-10-05 | 2010-10-04 | Pharmaceutical preparation comprising recombinant hcg |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2486051T3 true DK2486051T3 (da) | 2020-06-22 |
Family
ID=41471027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10763000.6T DK2486051T3 (da) | 2009-10-05 | 2010-10-04 | Farmaceutisk præparat, der omfatter rekombinant hcg |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8975226B2 (enEXAMPLES) |
| EP (2) | EP3611185B1 (enEXAMPLES) |
| JP (6) | JP6176924B2 (enEXAMPLES) |
| KR (7) | KR101804479B1 (enEXAMPLES) |
| CN (1) | CN107050434B (enEXAMPLES) |
| AR (2) | AR079876A1 (enEXAMPLES) |
| AU (1) | AU2010304922B2 (enEXAMPLES) |
| BR (1) | BR112012007990A2 (enEXAMPLES) |
| CA (1) | CA2776790A1 (enEXAMPLES) |
| DK (1) | DK2486051T3 (enEXAMPLES) |
| ES (2) | ES3036152T3 (enEXAMPLES) |
| HR (1) | HRP20200941T1 (enEXAMPLES) |
| HU (1) | HUE050793T2 (enEXAMPLES) |
| IL (3) | IL218548A (enEXAMPLES) |
| IN (1) | IN2012DN02073A (enEXAMPLES) |
| JO (1) | JOP20200039A1 (enEXAMPLES) |
| LT (1) | LT2486051T (enEXAMPLES) |
| MX (1) | MX2012003951A (enEXAMPLES) |
| PL (1) | PL2486051T3 (enEXAMPLES) |
| PT (1) | PT2486051T (enEXAMPLES) |
| RS (1) | RS60413B1 (enEXAMPLES) |
| RU (2) | RU2588650C2 (enEXAMPLES) |
| SI (1) | SI2486051T1 (enEXAMPLES) |
| TW (2) | TWI604850B (enEXAMPLES) |
| WO (1) | WO2011042688A1 (enEXAMPLES) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| CA3163525A1 (en) * | 2011-03-31 | 2012-10-04 | Ferring Bv. | Pharmaceutical preparation |
| WO2012168680A1 (en) * | 2011-06-06 | 2012-12-13 | Ferring B.V. | Pharmaceutical preparation comprising recombinant fsh |
| JO3092B1 (ar) * | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| AU2012340501A1 (en) * | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| CN108642030A (zh) | 2012-12-10 | 2018-10-12 | 生化学工业株式会社 | 新重组因子c、其制造方法、及内毒素的测定法 |
| JP2018500934A (ja) * | 2014-12-22 | 2018-01-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｍｐ依存性シアリダーゼ活性 |
| RS61163B1 (sr) * | 2015-04-24 | 2021-01-29 | Ferring Bv | Postupak proizvodnje gonadotrofina |
| KR102714934B1 (ko) * | 2015-06-26 | 2024-10-07 | 훼링 비.브이. | 정제 방법 및/또는 바이러스 불활화 처리 방법 |
| FI3787667T3 (fi) | 2018-04-30 | 2025-07-04 | Ferring Bv | Koostumus munasarjojen hallittua stimulaatiota varten |
| CA3168469A1 (en) * | 2020-02-05 | 2021-08-12 | Novartis Ag | Cho cell expressing il-15 heterodimers |
| CN116199742B (zh) * | 2022-07-06 | 2025-01-24 | 华兰基因工程有限公司 | 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| DK49987A (da) | 1987-01-30 | 1988-07-31 | Nordisk Gentofte | Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden |
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| BR9510567A (pt) * | 1995-03-21 | 1998-06-23 | Applied Research Systems | Formulaçoes líquidas de hcg |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| CN1302010C (zh) | 1997-06-25 | 2007-02-28 | 应用研究系统Ars股份公司 | 二硫键交联的糖蛋白激素类似物及其制备和应用 |
| US6500627B1 (en) | 1998-02-03 | 2002-12-31 | The Trustees Of Columbia University In The City Of New York | Methods for predicting pregnancy outcome in a subject by HCG assay |
| WO2000067778A1 (en) * | 1999-05-07 | 2000-11-16 | Applied Research Systems Ars Holding N.V. | Gonadotrophins |
| RS50741B (sr) * | 2000-02-22 | 2010-08-31 | Laboratoires Serono Sa. | Proces prečišćavanja rekombinantnog hcg |
| BR0212429A (pt) | 2001-09-12 | 2004-10-26 | Applied Research Systems | Uso de hcg na hiperestimulação ovariana controlada |
| HRP20040278B1 (hr) | 2001-10-22 | 2008-03-31 | Laboratoires Serono Sa | Gonadotropini za folikulogenezu |
| JP4583029B2 (ja) | 2001-10-29 | 2010-11-17 | クルセル ホランド ベー ヴェー | 所定の翻訳後修飾を有する蛋白質の製造方法及び製造手段 |
| AU2002224199A1 (en) * | 2001-10-29 | 2003-06-23 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
| CN1374525A (zh) * | 2001-12-31 | 2002-10-16 | 陕西超英生物医学研究开发有限公司 | 一种抗体芯片、其制备技术及其检测方法 |
| US7153824B2 (en) * | 2003-04-01 | 2006-12-26 | Applied Research Systems Ars Holding N.V. | Inhibitors of phosphodiesterases in infertility |
| EP2338333B1 (en) * | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Glycopegylation methods and proteins/peptides produced by the methods |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| JP4518464B2 (ja) | 2003-06-30 | 2010-08-04 | ミヨシ油脂株式会社 | 紙類処理剤及び紙類 |
| US8017388B2 (en) * | 2003-08-18 | 2011-09-13 | Glycotope Gmbh | Tumour cell lines and uses thereof |
| CA2554968C (en) * | 2004-02-04 | 2012-03-27 | Centre National De La Recherche Scientifique | Process for screening glycoform-specific antibodies |
| EP1725673A1 (en) * | 2004-02-13 | 2006-11-29 | Glycotope Gmbh | Sialytated glycoproteins-process conditions and an efficient method for their production |
| CA2598528A1 (en) * | 2005-03-11 | 2006-09-14 | Fresenius Kabi Deutschland Gmbh | Production of bioactive glycoproteins from inactive starting material |
| DE112006002122B4 (de) | 2005-08-15 | 2016-09-22 | Continental Automotive Systems, Inc. ( n. d. Ges. d. Staates Delaware ) | Dieselabgas-Kohlenwasserstoff-Dosierventil für Fahrzeuge |
| RU2309411C2 (ru) * | 2005-11-24 | 2007-10-27 | Ростовский НИИ акушерства и педиатрии МЗ РФ | Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами |
| KR100809945B1 (ko) * | 2006-02-01 | 2008-03-05 | 대한민국 | 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법 |
| WO2008011633A2 (en) * | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| EP2054521A4 (en) * | 2006-10-03 | 2012-12-19 | Novo Nordisk As | PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| CA3163525A1 (en) * | 2011-03-31 | 2012-10-04 | Ferring Bv. | Pharmaceutical preparation |
| JO3092B1 (ar) * | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
-
2010
- 2010-09-27 TW TW104140348A patent/TWI604850B/zh active
- 2010-09-27 TW TW099132570A patent/TWI532495B/zh active
- 2010-10-04 AU AU2010304922A patent/AU2010304922B2/en active Active
- 2010-10-04 KR KR1020127008827A patent/KR101804479B1/ko active Active
- 2010-10-04 ES ES19190372T patent/ES3036152T3/es active Active
- 2010-10-04 RU RU2012112907/10A patent/RU2588650C2/ru active
- 2010-10-04 KR KR1020217037028A patent/KR102489143B1/ko active Active
- 2010-10-04 US US13/500,274 patent/US8975226B2/en active Active
- 2010-10-04 WO PCT/GB2010/001854 patent/WO2011042688A1/en active Application Filing
- 2010-10-04 LT LTEP10763000.6T patent/LT2486051T/lt unknown
- 2010-10-04 IN IN2073DEN2012 patent/IN2012DN02073A/en unknown
- 2010-10-04 KR KR1020197007226A patent/KR101987982B1/ko active Active
- 2010-10-04 PL PL10763000T patent/PL2486051T3/pl unknown
- 2010-10-04 EP EP19190372.3A patent/EP3611185B1/en active Active
- 2010-10-04 RU RU2016118236A patent/RU2724528C2/ru active
- 2010-10-04 KR KR1020177034392A patent/KR20170133531A/ko not_active Withdrawn
- 2010-10-04 HU HUE10763000A patent/HUE050793T2/hu unknown
- 2010-10-04 RS RS20200698A patent/RS60413B1/sr unknown
- 2010-10-04 EP EP10763000.6A patent/EP2486051B1/en active Active
- 2010-10-04 BR BR112012007990A patent/BR112012007990A2/pt not_active Application Discontinuation
- 2010-10-04 KR KR1020237001308A patent/KR20230012104A/ko active Pending
- 2010-10-04 DK DK10763000.6T patent/DK2486051T3/da active
- 2010-10-04 SI SI201032015T patent/SI2486051T1/sl unknown
- 2010-10-04 HR HRP20200941TT patent/HRP20200941T1/hr unknown
- 2010-10-04 KR KR1020197016021A patent/KR102213154B1/ko active Active
- 2010-10-04 JP JP2012532657A patent/JP6176924B2/ja active Active
- 2010-10-04 CA CA2776790A patent/CA2776790A1/en active Pending
- 2010-10-04 PT PT107630006T patent/PT2486051T/pt unknown
- 2010-10-04 KR KR1020217003233A patent/KR20210014767A/ko not_active Ceased
- 2010-10-04 ES ES10763000T patent/ES2798258T3/es active Active
- 2010-10-04 MX MX2012003951A patent/MX2012003951A/es active IP Right Grant
- 2010-10-04 CN CN201610832288.8A patent/CN107050434B/zh active Active
- 2010-10-05 AR ARP100103608A patent/AR079876A1/es not_active Application Discontinuation
-
2012
- 2012-03-08 IL IL218548A patent/IL218548A/en active IP Right Grant
-
2014
- 2014-05-21 US US14/283,904 patent/US9676835B2/en active Active
-
2015
- 2015-11-09 JP JP2015219480A patent/JP6310440B2/ja active Active
-
2017
- 2017-02-23 IL IL250733A patent/IL250733B/en active IP Right Grant
- 2017-05-03 US US15/586,010 patent/US10526390B2/en active Active
- 2017-10-24 JP JP2017205012A patent/JP6580104B2/ja active Active
-
2019
- 2019-06-20 IL IL267556A patent/IL267556A/en unknown
- 2019-08-27 JP JP2019154226A patent/JP7292153B2/ja active Active
- 2019-12-10 US US16/709,810 patent/US11292824B2/en active Active
-
2020
- 2020-02-17 JO JOP/2020/0039A patent/JOP20200039A1/ar unknown
-
2021
- 2021-07-12 JP JP2021114833A patent/JP7196244B2/ja active Active
-
2022
- 2022-03-30 US US17/709,296 patent/US12234272B2/en active Active
- 2022-05-27 AR ARP220101408A patent/AR125991A2/es not_active Application Discontinuation
-
2023
- 2023-02-22 JP JP2023025781A patent/JP2023075144A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2486051T3 (da) | Farmaceutisk præparat, der omfatter rekombinant hcg | |
| NO2017031I1 (no) | insulin aspart | |
| SMT201700008B (it) | Composizione farmaceutica | |
| IL245328A0 (en) | Pharmaceutical composition | |
| SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
| DK3097925T3 (da) | Farmaceutisk sammensætning | |
| BRPI1004940A2 (pt) | composição farmacêutica | |
| BR112012011902A2 (pt) | cápsula farmacêutica | |
| DK2536830T3 (da) | Polypeptider | |
| BR112013017629A2 (pt) | laminina-521 recombinante | |
| LT3061445T (lt) | Labai koncentruotos farmacinės kompozicijos | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| EP2654736A4 (en) | NEW PHARMACEUTICAL COMPOSITION | |
| BRPI1015939A2 (pt) | composição farmacêutica | |
| EE201300005A (et) | Ravimkoostis | |
| BRPI1016190A2 (pt) | compostos farmacêuticos. | |
| BRPI0922653A2 (pt) | preparação farmacêutica | |
| DK2437736T3 (da) | Lægemiddelindgivelsessystemer | |
| BR112013008074A2 (pt) | combinações farmacêuticas | |
| BR112012003149A2 (pt) | composição farmacêutica | |
| DK2389166T3 (da) | Farmaceutisk sammensætning omfattende aleglitazar | |
| BR112012029461A2 (pt) | composição farmacêutica contendo solifenacina | |
| BR112012029887A2 (pt) | composição farmacêutica | |
| FI20105327L (fi) | Farmaseuttinen koostumus | |
| BRPI1008983A2 (pt) | formulação farmacêutica |